title: Amantadine for chronic hepatitis C: pilot study in 14 patients.
abstract: BACKGROUND
  Amantadine, a widely available antiviral drug, has been previously reported to be effective in patients with chronic hepatitis C who failed to respond to interferon-alpha therapy. Nevertheless, its efficacy has not been fully studied, particularly in naive patients.
  
  
  OBJECTIVE
  We conducted a pilot study to determine the efficacy and the safety of amantadine as initial therapy in patients with chronic hepatitis C.
  
  
  METHODS
  Fourteen consecutive patients (mean age, 40 years; M/F ratio, 9/5) with chronic hepatitis C, elevated alanine aminotransferase (ALT) and without cirrhosis were treated with a 6-month course of amantadine, 100 mg orally twice daily. Main outcome measures were ALT concentrations and serum hepatitis C virus-RNA (HCV-RNA) levels at the end of therapy.
  
  
  RESULTS
  All adverse events were mild or moderate and were not treatment limiting. At the end of treatment, all patients had detectable serum HCV-RNA and only one patient had a normal ALT level. The serum HCV-RNA median level and the ALT median level were not significantly different at the end of treatment as compared to baseline levels.
  
  
  CONCLUSIONS
  Our results show that amantadine alone cannot be recommended as an alternative therapy in patients with chronic hepatitis C.
authors.affiliation: Hepatogastro-enterology Unit, H pital Louis Mourier, Colombes, France.
authors.forename: C
authors.initials: C
authors.lastname: Andant
authors.forename: J
authors.initials: J
authors.lastname: Lamoril
authors.forename: J C
authors.initials: JC
authors.lastname: Deybach
authors.forename: P
authors.initials: P
authors.lastname: Jouet
authors.forename: J C
authors.initials: JC
authors.lastname: Soulé
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000547:Amantadine / Q000008:administration & dosage* / Q000009:adverse effects; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012367:RNA, Viral / Q000032:analysis / Q000187:drug effects*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D000547:Amantadine